https://doi.org/10.1093/infdis/jiaf030 Background Long coronavirus disease (COVID), which affects an estimated 44.69–48.04 million people in the United States, is an ongoing public health concern that will persist as severe acute respiratory […]
COVID-19 Vaccine Boosters for Young Adults: A Risk-Benefit Assessment and Five Ethical Arguments against Mandates at Universities
Authors: Kevin Bardosh University of Washington; University of Edinburgh – Edinburgh Medical School Allison Krug Artemis Biomedical Communications LLC Euzebiusz Jamrozik University of Oxford Trudo Lemmens University of Toronto – […]
Big Pharma Can’t Figure Out How To Cash In On ‘Long COVID’
Authors:mmDYLAN HOUSMANHEALTHCARE REPORTER July 11, 2022 Major pharmaceutical companies are struggling to develop treatments for “long COVID” because it’s been nearly impossible to nail down what exactly the ailment actually […]
Serious Adverse Events of Special Interest Following mRNA Vaccination in Randomized Trials
Authors: Joseph Fraiman June 23, 2022 Louisiana State University – Lallie Kemp Regional Medical Center Abstract Introduction: In 2020, prior to COVID-19 vaccine rollout, the Coalition for Epidemic Preparedness Innovations […]
The Bizarre Refusal to Apply Cost-Benefit Analysis to COVID Debates
Are those who oppose a ban on cars or a radical reduction in speed limits sociopaths, given the huge number of people they are knowingly consigning to death or maiming? […]